Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its product candidates include DMT310 and DMT410. Its lead product candidate DMT310 is intended to utilize its Spongilla technology for the once-weekly treatment of a variety of skin diseases with its initial focus being on the treatment of acne vulgaris. DMT310 completed a Phase Ib proof of concept (POC) trial in psoriasis. Its second product candidate utilizing its Spongilla technology is its combination treatment, DMT410. DMT410 is intended to consist of one treatment of its sponge powder followed by one topical application of botulinum toxin for delivery into the dermis. DMT410 Phase I POC trial of DMT410 for the treatment of multiple aesthetic skin conditions, including reduction of pore size, sebum production, and fine lines.